Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes

References

• Crandall JP, Knowler WC, Kahn SE et al. The prevention of Type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab.4(7), 382–393 (2008).
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustments of therapy. Diabetes Care32, 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Little RR, Mokdad AH. Trends in A1c concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care31, 102–104 (2008).
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358, 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with Type 2 diabetes: a retrospective cohort study. Lancet375(9713), 481–489 (2010).
   PubMed Web of Science ®Google Scholar
• Zannad F. Implications of the ADVANCE study for clinical practice. J. Hypertens.26(3), S29–S32 (2008)
   Google Scholar
• Kilpatrick ES, Rigby AS, Atkin SL. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat. Rev. Endocrinol.5(10), 537–545 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss IA, Valiquette G, Schwarcz MD. Impact of glycemic treatment choices on cardiovascular complications in Type 2 diabetes. Cardiol. Rev.17(4), 165–175 (2009).
   Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355, 2424–2443 (2006).
   Google Scholar
• Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in Type 2 diabetes. Diabet. Med.25, 245–254 (2008).
   PubMed Web of Science ®Google Scholar
• Sesti G. Harnessing the weight-regulating properties of glucagon-like-peptide-1 in the treatment of Type 2 diabetes. Diabetes Obes. Metab.11(S3), 4–10 (2009).
   Google Scholar
• Álvarez Guisasola F, Tofé Povedano S, Krishnarajah G et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with Type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes. Metab.10(1), 25–32 (2008).
   PubMed Web of Science ®Google Scholar
• Hauber AB, Mohamed AF, Johnson FR et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet. Med.26, 416–424 (2009).
   PubMed Web of Science ®Google Scholar
• Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet370, 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• Ma J, Rayner CK, Jones KL, Horowitz M. Insulin secretion in healthy subjects and patients with Type 2 diabetes – role of the gastrointestinal tract. Best Pract. Res. Clin. Endocrinol. Metab.23(4), 413–424 (2009).
   PubMedGoogle Scholar
• Højberg PV, Vilsbøll T, Rabøl R et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with Type 2 diabetes. Diabetologia52(2), 199–207 (2009).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T. The effects of glucagon-like peptide-1 on the β-cell. Diabetes Obes. Metab.11(3), 11–18 (2009).
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Holst JJ, Knop FK. The spectrum of antidiabetic actions of GLP-1 in patients with Type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab.23(4), 453–462 (2009).
   PubMed Web of Science ®Google Scholar
• Deacon CF. What do we know about secretion and degradation of incretin hormones? Regul. Pept.128, 117–124 (2005).
   PubMed Web of Science ®Google Scholar
• Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in Type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care24, 1416–1421(2001).
   PubMed Web of Science ®Google Scholar
• Bailey C. New therapies for diabesity. Curr. Diab. Rep.9(5), 360–367 (2009).
   Google Scholar
• Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab.23(4), 463–477 (2009).
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Zdravkovic M, Lee-Thi T et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes mellitus. Diabetes Care30, 1608–1610 (2007).
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J. The GLP_1 derivative NN2211 restores β-cell sensitivity to glucose in Type 2 diabetic patients after a single dose. Diabetes52, 1786–1791 (2003).
   PubMed Web of Science ®Google Scholar
• Degn KB, Juhl CB, Sturis J et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative (NN2211) markedly improves 24-h glycemia and a and β-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes53, 1187–1194 (2004).
   PubMed Web of Science ®Google Scholar
• Bregenholt S, Moldrup A, Blume N et al. The long-acting glucagon-like peptide-1 analog, liraglutide inhibits β-cell apoptosis in vitro. Biochem. Biophys. Res. Commun.330, 577–584 (2005).
   PubMed Web of Science ®Google Scholar
• Toso C, McCall M, Merani S et al. Liraglutide,a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl. Int.23(3), 259–265 (2009).
   Google Scholar
• Vilsbøll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet. Med.25(2), 152–156 (2008).
   PubMed Web of Science ®Google Scholar
• Juhl CB, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in Type 2 diabetes. Diabetes51, 424–429 (2002).
   PubMed Web of Science ®Google Scholar
• Horowitz M, Flint A, Doran S et al. Effects of the once-daily human GLP-1 analog liraglutide on appetite and energy intake in Type 2 diabetes. Diabetologia51, S355 (2008).
   Google Scholar
• Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in Type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care32(1), 84–90 (2009).
   PubMed Web of Science ®Google Scholar
• Zinman B, Jerich J, Buse JB et al. Efficacy and safety of the glucagon-like peptide 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 MET+TZD) Diabetes Care32, 1224–1230 (2009).
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomized, parallel-group, multi-national, open-label trial (LEAD-6). Lancet374, 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet374, 1606–1616 (2009).
   PubMed Web of Science ®Google Scholar
• Raun K, Von-Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity15, 1710–1716 (2007).
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet373, 473–481 (2008).
   PubMed Web of Science ®Google Scholar
• Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab.11(12), 1163–1172 (2009).
   PubMed Web of Science ®Google Scholar
• Courreges JP, Vilsboll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med.25(9), 1129–1131 (2008).
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes58, 975–983 (2009).
   PubMed Web of Science ®Google Scholar
• Fonseca V, Madsbad S, Falahati A, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP – a meta-analysis of 6 clinical trials. 545-P 69th Scientific Session American Diabetes Association. LA, USA, 5–9 June 2009.
   Google Scholar
• Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol.201(1), 59–66 (2009).
   PubMed Web of Science ®Google Scholar
• Bjornsdottir I, Olsen A, Larsen U et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia51, S356 (2008).
   Web of Science ®Google Scholar
• Elbrond B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care25, 1398–1404 (2002).
   PubMed Web of Science ®Google Scholar
• Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyam S. Tolerability, pharmacokinetics, and pharmacodynamics of the once-daily human GLP-1 analogue liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int. J. Clin. Pharmacol. Ther.46, 273–279 (2008).
   PubMed Web of Science ®Google Scholar
• Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily human glucagon-like peptide 1 analogue liraglutide. J. Clin. Pharmacol.46, 635–641 (2006).
   PubMed Web of Science ®Google Scholar
• Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Diabetes57, A593 (2008).
   Web of Science ®Google Scholar
• Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol.68(6), 898–905 (2009).
   PubMed Web of Science ®Google Scholar
• Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide Diabetes56, A145 (2007).
   Web of Science ®Google Scholar
• Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycaemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care27, 1335–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting glucagon-like peptide 1 analog, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med.22(8), 1016–1023 (2005).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211–1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and body weight in subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes114(8), 417–423 (2006).
   PubMed Web of Science ®Google Scholar
• Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 analog, on glycemic control and body composition and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care27(8), 1915–1921 (2004).
   PubMed Web of Science ®Google Scholar
• Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract.81(2), 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Rev. Endocrinol. Metab.4(2), 119–129 (2009).
   PubMedGoogle Scholar
• Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med.26(3), 268–278 (2009).
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met+SU: a randomised controlled trial. Diabetologia52(10), 2046–2055 (2009).
   PubMed Web of Science ®Google Scholar
• Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with Type 2 diabetes. Curr. Med. Res. Opin.26(5), 1013–1022 (2010).
   PubMed Web of Science ®Google Scholar
• Kaku K, Rasmussen MF, Clauson P, Seinov Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with Type 2 diabetes. Diabetes Obes. Metab.12(4), 341–347 (2010).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care33, 428–433 (2010).
   PubMed Web of Science ®Google Scholar